"Hermanos Ameijeiras" Surgical Clinical Hospital
Welcome,         Profile    Billing    Logout  
 9 Trials 
20 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
García, Yolanda
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Checkmark [VIRTUAL] MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with hi.…
Recruiting
3
430
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
ImmunoGen, Inc., Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groupbs
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
07/22
09/23
OVAL, NCT03398655: A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Checkmark Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resis…
Checkmark [VIRTUAL] Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
Checkmark [VIRTUAL] Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
Checkmark Ofranergene obadenovec (VB-111) an anti-cancer gene therapy induces immunotherapeutic effect in platinum resistant ovarian cancer: Histopathology findings
Checkmark Ofranergene obadenovec (VB-111) an anti-cancer gene therapy induces immunotherapeutic effect in platinum resistant ovarian cancer: Histopathology findings
More
Recruiting
3
400
Europe, Japan, US, RoW
VB-111 + Paclitaxel, Ofranergene Obadenovec, Placebo + Paclitaxel
Vascular Biogenics Ltd. operating as VBL Therapeutics, GOG Foundation
Recurrent Platinum Resistant Ovarian Cancer
12/22
06/23
ANITA, NCT03598270 / 2018-000366-11: Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Checkmark A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment…
Checkmark ENGOT-Ov41/ GEICO-69-O/ ANITA trial: A Phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or per…
Recruiting
3
414
Europe
Placebo, Placebo of Atezolizumab, Carboplatin, Paclitaxel, Niraparib, Gemcitabine, Pegylated liposomal doxorubicin (PLD), Atezolizumab, Tecentriq
Grupo Español de Investigación en Cáncer de Ovario, Hoffmann-La Roche, GlaxoSmithKline, AGO Study Group, Belgian Gynaecological Oncology Group, ARCAGY/ GINECO GROUP, Israeli Society of Gynecologic Oncology, MaNGO
Recurrent Ovarian Carcinoma
08/24
01/25
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
ATOMICC, NCT03833479 / 2018-002155-15: TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Checkmark [VIRTUAL] Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
Recruiting
2
132
Europe, RoW
No Further Treatment, TSR-042
Grupo Español de Investigación en Cáncer de Ovario, TESARO/GSK, Apices Soluciones S.L.
Cervical Cancer, Advanced Cancer
07/23
07/23
García, Jorge I
NCT03559543: Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Recruiting
2
40
RoW
Ocoxin-Viusid
Catalysis SL
Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Rectal Diseases, Colonic Diseases, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
11/20
01/21
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
NCT03496766: Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Recruiting
2
18
Europe
Tipifarnib, Zarnestra
Spanish Lung Cancer Group
Non Small Cell Lung Cancer
01/23
10/23
Pérez, Mayte Lima
NCT03559543: Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Recruiting
2
40
RoW
Ocoxin-Viusid
Catalysis SL
Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Rectal Diseases, Colonic Diseases, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
11/20
01/21
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Diéguez, Robin García
NCT03559543: Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

Recruiting
2
40
RoW
Ocoxin-Viusid
Catalysis SL
Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Rectal Diseases, Colonic Diseases, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
11/20
01/21
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Calvo, Vilma Fleites
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Ortiz, Jorge
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Suardiaz, María E
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Cascudo, Amarilis Grau
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Fleites, Ivelisse
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Domínguez, Carlos
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Gutiérrez, Angela
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21
Pérez, Mayté Lima
NCT03717298: Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma

Recruiting
2
30
RoW
Ocoxin-Viusid®
Catalysis SL
Adenocarcinoma of the Pancreas, Pancreatic Cancer, Advanced Cancer, Digestive System Neoplasms, Pancreatic Neoplasms, Endocrine Gland Neoplasms, Digestive System Diseases, Endocrine System Diseases, Pancreatic Diseases
02/21
06/21

Download Options